SCHEDULE: BVF Partners Discloses 9.99% Stake in Tenax Therapeutics

Biotechnology Value Fund and affiliates report a 9.99% beneficial ownership stake in Tenax Therapeutics, Inc. via Schedule 13G filing.

Summary

• Biotechnology Value Fund (BVF) and its affiliates reported a collective beneficial ownership of 1,908,722 shares of Tenax Therapeutics, Inc. common stock.
• The reported stake represents 9.99% of the company's outstanding shares as of March 31, 2026.
• The holdings include 1,569,173 shares underlying pre-funded warrants, subject to a 9.99% ownership blocker.
• The reporting group includes multiple entities managed by Mark N. Lampert, including BVF, BVF2, and various holding companies.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive indicator, as it confirms continued institutional support from a known biotech investor without signaling an immediate change in corporate strategy.

Positives

• Significant institutional backing from a specialized biotechnology investment firm.
• The investment group maintains a long-term interest in the company's clinical progress.

Negatives

• Ownership is heavily reliant on pre-funded warrants rather than direct common stock holdings.
• Exercise of warrants is restricted by a 9.99% beneficial ownership blocker, limiting immediate voting control.

Risks

• Warrant exercise is subject to a 9.99% ownership blocker, which may limit the ability of the investor to increase their position significantly without regulatory or contractual hurdles.
• Warrants expire based on the timing of the Phase 3 LEVEL trial topline data announcement, creating a binary risk event for the value of these derivative holdings.
• The investment is subject to market volatility inherent in clinical-stage biotechnology companies.

Future Outlook

The reporting group maintains its position pending the outcome of the Phase 3 LEVEL trial. The expiration of warrants is tied to the timing of the topline data announcement for this trial.

Management Comments

• The reporting persons certify that the securities were not acquired for the purpose of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that institutional filings from specialized biotech funds like BVF often signal confidence in upcoming clinical trial readouts, particularly for companies in the Phase 3 stage of development.

Comparison to Industry Standards

• The 9.99% ownership threshold is a standard 'blocker' limit used by institutional investors in small-cap biotech to avoid triggering change-of-control provisions or complex regulatory filings.
• The use of pre-funded warrants is a common financing structure in the biotech sector to provide capital while deferring immediate dilution.

Stakeholder Impact

• Shareholders may view the continued 9.99% stake as a sign of stability.
• The existence of significant warrant overhang may impact future share price appreciation due to potential dilution.

Next Steps

• Monitor for the Phase 3 LEVEL trial topline data announcement.
• Observe potential warrant exercises following the data release.

Key Dates

Recommendation

The filing represents a routine disclosure of existing institutional holdings. While it confirms support, it does not indicate a new strategic shift or material change in the company's fundamental outlook.

Keywords

Tenax Therapeutics, BVF Partners, Schedule 13G, Biotechnology, Institutional Ownership, Warrants